Is Nautilus Biotechnology profitable in 2026?

No. Nautilus reported a $14.7M net loss in Q1 2026 alone, following a $59.0M full-year loss in 2025. Management guided to only about $0.5M in total FY2026 revenue, mostly from grant funding, as stated June 2, 2026.

Has Nautilus Biotechnology had layoffs?

Yes. In February 2025, Nautilus cut 16% of its workforce, reducing headcount from 158 to 133 employees, explicitly to extend cash runway into 2027. Headcount stood at 127 as of March 31, 2026.

Who is Nautilus Biotechnology's biggest competitor?

Quantum-Si already ships a commercial single-molecule protein sequencer, Seer's Proteograph has appeared in 58+ papers, and Thermo Fisher owns the mass-spec gold standard plus Olink. As of July 2026, Nautilus's Voyager platform has not yet launched commercially.

Could AI replace Nautilus Biotechnology?

Not directly. Nautilus's core value is physical wet-lab measurement of proteins via its Voyager instrument, which AI software cannot replicate. It does use machine learning internally to convert raw binding data into protein identifications, described as part of its pipeline as of February 24, 2026.

Who owns Nautilus Biotechnology?

Nautilus is a public company on Nasdaq under ticker NAUT. Andreessen Horowitz-affiliated funds remain a major holder near 10%, despite selling roughly 5M shares in block trades on June 2, 2026 at $2.35 and June 26, 2026 at $2.00.

When will Nautilus Biotechnology launch its Voyager product commercially?

Per April 27, 2026 guidance, Nautilus expects pre-orders in late 2026, customer installations starting early 2027, and broad-scale commercial availability in H1 2027, coinciding closely with its projected cash runway limit.

Biotech tools companies · United States

Nautilus Biotechnology

nautilusbio.com ↗

Pre-revenue biotech building Voyager, a single-molecule protein-sequencing instrument.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from July 28, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report

The call

Nautilus has real science and cash to reach its 2027 launch, but zero sales capacity and no independent benchmark leave the outcome to execution, not any protection from Thermo Fisher or AI.

Nautilus Biotechnology built a machine called Voyager that reads proteins one at a time, a technique called single-molecule proteomics. The company has solid research backing and real patents, but it has not sold anything yet even though it went public five years ago, and its money runs out almost exactly when it plans to start selling in mid-2027. Copying this technology is hard because it requires deep science and custom equipment, but Thermo Fisher (which already dominates protein testing) could enter this market anytime, and smaller rivals like Quantum-Si and Seer are already shipping their own versions. The one thing that could save Nautilus is if actual customers outside of research grants place real orders in early 2027 and stick around to buy more, proving the machine actually works better than competitors in the real world.

Why

AI pressure: None apparent. AI drug-discovery labs need more protein data, so AI demand feeds Nautilus's market rather than eating it. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher. Thermo's mass-spec instruments and Olink affinity panels already sell into the same proteomics budgets Nautilus needs to win. Could a giant copy it? Yes, easily.

What protects it. Genuine single-molecule protein IP and $143.4M cash, but neither has been tested against a paying customer yet.

What would change this call

Nautilus Q2 2026 earnings on July 28, 2026 report cash burn and launch timeline. Shows whether the H1 2027 commercial launch and cash runway stay on track.
Named commercial pre-orders (10+ sites) beyond grant-funded partners by late 2026. Would show real paying-customer demand rather than subsidized early access.
Thermo Fisher announces or acquires a single-molecule proteomics platform. Would show the dominant incumbent moving directly into Nautilus's market.

Key numbers

$143.4M cash and investments as of Q1 2026 (2026-03-31)
FY2025 net loss $59.0M, down from $70.8M (2026-02-26)
FY2026 revenue guided at just $0.5M (2026-06-02)

Named risks

Cash runway extends only into 2027, same window as guided H1 2027 commercial launch. Severity: high
Zero sales capacity confirmed as of Q4 2025 earnings call ahead of planned 2026 pre-orders. Severity: high
No independent third-party benchmark yet validates Voyager's claimed performance advantage. Severity: high
Prior Nasdaq delisting notice for sub-$1.00 bid price shows fragile compliance margin. Severity: medium
Major early backer Andreessen Horowitz selling shares in block trades through mid-2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Quantum-Si	losing to	Quantum-Si's Platinum is the only commercially shipping single-molecule protein sequencer as of 2026
Seer Inc	losing to	Seer's Proteograph cited in 58+ published papers as of 2025, ahead in adoption
Thermo Fisher	contesting	Owns mass-spec gold standard and Olink, no structural barrier to entering single-molecule proteomics
SomaLogic	losing to	SomaScan shows 10,000+ protein coverage per independent 2025-01-07 benchmark

Questions people ask

Is Nautilus Biotechnology profitable in 2026?: No. Nautilus reported a $14.7M net loss in Q1 2026 alone, following a $59.0M full-year loss in 2025. Management guided to only about $0.5M in total FY2026 revenue, mostly from grant funding, as stated June 2, 2026.
Has Nautilus Biotechnology had layoffs?: Yes. In February 2025, Nautilus cut 16% of its workforce, reducing headcount from 158 to 133 employees, explicitly to extend cash runway into 2027. Headcount stood at 127 as of March 31, 2026.
Who is Nautilus Biotechnology's biggest competitor?: Quantum-Si already ships a commercial single-molecule protein sequencer, Seer's Proteograph has appeared in 58+ papers, and Thermo Fisher owns the mass-spec gold standard plus Olink. As of July 2026, Nautilus's Voyager platform has not yet launched commercially.
Could AI replace Nautilus Biotechnology?: Not directly. Nautilus's core value is physical wet-lab measurement of proteins via its Voyager instrument, which AI software cannot replicate. It does use machine learning internally to convert raw binding data into protein identifications, described as part of its pipeline as of February 24, 2026.
Who owns Nautilus Biotechnology?: Nautilus is a public company on Nasdaq under ticker NAUT. Andreessen Horowitz-affiliated funds remain a major holder near 10%, despite selling roughly 5M shares in block trades on June 2, 2026 at $2.35 and June 26, 2026 at $2.00.
When will Nautilus Biotechnology launch its Voyager product commercially?: Per April 27, 2026 guidance, Nautilus expects pre-orders in late 2026, customer installations starting early 2027, and broad-scale commercial availability in H1 2027, coinciding closely with its projected cash runway limit.

Timeline

2026-06-26a16z-affiliated funds sell Nautilus shares at $2.00, retaining near-10% stake
2026-06-02Q1 2026 earnings transcript confirms ~$0.5M FY2026 revenue guidance, mostly grants
2026-04-28Q1 2026 results: $14.7M net loss, $12.8M burn, $143.4M cash on hand
2026-03-26Baylor College of Medicine named first Early Access Program customer
2026-02-26FY2025 results: $59.0M net loss, down from $70.8M in 2024
2026-02-24Voyager platform unveiled at US HUPO 2026, up to 10B proteins per run
2026-01Iterative Mapping Early Access Program launches with tau proteoforms assay
2025-05-05Nasdaq delisting notice issued for failing $1.00 minimum bid price
2025-02-2716% workforce layoff announced, headcount cut from 158 to 133
2021-06-09SPAC merger with ARYA Sciences Acquisition Corp III closes, ~$345M raised

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation